Stockscreener 앱 받기
0.7723
6.32%
-0.0521
시간 외 거래:
.82
0.0477
+6.18%
전일 마감가:
$0.8244
열려 있는:
$0.825
하루 거래량:
1.25M
Relative Volume:
0.91
시가총액:
$45.41M
수익:
-
순이익/손실:
$-123.46M
주가수익비율:
-0.2982
EPS:
-2.59
순현금흐름:
$-104.11M
1주 성능:
-4.65%
1개월 성능:
-2.24%
6개월 성능:
+90.46%
1년 성능:
-46.74%
1일 변동 폭
$0.7404
$0.8793
1주일 범위
$0.7404
$0.8793
52주 변동 폭
$0.2601
$1.4675
바이오아틀라 Stock (BCAB) Company Profile
명칭
Bioatla Inc
전화
858-558-0708
주소
11085 TORREYANA ROAD, SAN DIEGO
BCAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.7723 | 48.47M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
바이오아틀라 Stock (BCAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-13 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 개시 | JMP Securities | Mkt Outperform |
| 2022-05-05 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-06-28 | 개시 | ROTH Capital | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | BTIG Research | Buy |
| 2021-01-11 | 개시 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | JP Morgan | Overweight |
| 2021-01-11 | 개시 | Jefferies | Buy |
모두보기
바이오아틀라 주식(BCAB)의 최신 뉴스
Acorn Capital Advisors LLC Has $1.92 Million Stock Holdings in BioAtla, Inc. $BCAB - Defense World
What drives BioAtla Inc stock priceIndustrial Stocks Review & Exceptional Capital Trading - earlytimes.in
Taking on analysts’ expectations and winning: BioAtla Inc (BCAB) - setenews.com
Is BioAtla Inc. stock positioned well for digital economyTrade Risk Report & Safe Entry Trade Signal Reports - Newser
Will BioAtla Inc. stock continue dividend increasesJuly 2025 Levels & Stepwise Entry and Exit Trade Signals - Newser
Why BioAtla Inc. stock is considered a top pickDollar Strength & High Return Trade Opportunity Guides - Newser
Biotech Momentum Builds In After-Hours Trading As BioAtla, Entero, And Sonnet Climb - Nasdaq
Can BioAtla Inc. stock rebound after recent weaknessMarket Rally & Low Risk Growth Stock Ideas - moha.gov.vn
BioAtla, Inc. (BCAB) -11.3% in Intraday Trading: What’s Driving the Move? - Stocks Telegraph
BioAtla Inc. (BCAB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
The growth track for BioAtla Inc (BCAB) has changed recently - setenews.com
[PRE 14A] BioAtla, Inc. Preliminary Proxy Statement - Stock Titan
BioAtla Reports Q3 2025 Financial Results and Progress - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Form 424B5 BioAtla, Inc. - StreetInsider
[424B5] BioAtla, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
BioAtla Secures $7.5 Million Pre-Paid Advance - TipRanks
[8-K] BioAtla, Inc. Reports Material Event | BCAB SEC FilingForm 8-K - Stock Titan
BioAtla’s New Funding: A Double-Edged Sword for Shareholders - Ad-hoc-news.de
BioAtla Agrees to $22.5 Million in Financing Agreements - MarketScreener
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - Investing News Network
BioAtla, Inc. Secures $7.5 Million Financing to Support Operations During Strategic Partnership Negotiations - Quiver Quantitative
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - GlobeNewswire Inc.
Is BioAtla Inc (BCAB) Good For Your Portfolio? - fostersleader.com
Regression analysis insights on BioAtla Inc. performanceWeekly Trend Summary & AI Enhanced Market Trend Forecasts - newser.com
What catalysts could drive BioAtla Inc. stock higherProfit Target & Fast Gain Swing Trade Alerts - newser.com
Measuring BioAtla Inc.’s beta against major indicesTrade Analysis Report & Community Consensus Trade Alerts - newser.com
Ewing Sarcoma Market Research Report 2025-2035: Salarius, Eli Lilly, Pfizer, and BioAtla Lead by Driving Innovations in the Development of Novel Targeted Therapies - Yahoo Finance
BioAtla Inc. stock outlook for YEAR2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - newser.com
Bioatla Shares Surge on Strong Clinical and Financial Results - Ad-hoc-news.de
Sentiment analysis tools applied to BioAtla Inc.Take Profit & Verified Momentum Watchlists - newser.com
What moving averages say about BioAtla Inc.Portfolio Return Summary & Accurate Entry/Exit Alerts - newser.com
BioAtla Inc (BCAB) can make a big difference with a little luck - Setenews
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch - MSN
Analyzing BioAtla Inc. with multi timeframe chartsMarket Sentiment Report & High Accuracy Swing Entry Alerts - newser.com
Analyzing BioAtla Inc. with risk reward ratio chartsTrade Performance Summary & Weekly Watchlist of Top Performers - newser.com
BioAtla, Inc.Common Stock (Nasdaq:BCAB) Stock Quote - Markets Financial Content
What to do if you’re stuck in BioAtla Inc.Sell Signal & Reliable Price Action Trade Plans - newser.com
Chart overlay techniques for tracking BioAtla Inc.July 2025 Sentiment & Technical Confirmation Alerts - newser.com
Is BioAtla Inc. a candidate for recovery playGap Down & AI Powered Trade Plan Recommendations - newser.com
BioAtla Tightens Belt But Analysts Remain Upbeat - Finimize
바이오아틀라 (BCAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):